Pevonedistat
- Generic Name
- Pevonedistat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25N5O4S
- CAS Number
- 905579-51-3
- Unique Ingredient Identifier
- S3AZD8D215
- Background
Pevonedistat has been used in trials studying the treatment of Lymphoma, Solid Tumors, Multiple Myeloma, Hodgkin Lymphoma, and Metastatic Melanoma, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
Phase 2
Active, not recruiting
- Conditions
- Stage IV Hepatocellular Carcinoma AJCC v8Stage IV Intrahepatic Cholangiocarcinoma AJCC v8Stage IVB Hepatocellular Carcinoma AJCC v8Metastatic Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8Unresectable Intrahepatic CholangiocarcinomaStage III Intrahepatic Cholangiocarcinoma AJCC v8Stage IIIA Hepatocellular Carcinoma AJCC v8Unresectable CholangiocarcinomaStage IIIA Intrahepatic Cholangiocarcinoma AJCC v8
- Interventions
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT04175912
- Locations
- 🇺🇸
McFarland Clinic - Jefferson, Jefferson, Iowa, United States
🇺🇸Advanced Breast Care Center PLLC, Warren, Michigan, United States
🇺🇸Katmai Oncology Group, Anchorage, Alaska, United States
Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia
Phase 1
Active, not recruiting
- Conditions
- Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaTherapy-Related Acute Myeloid LeukemiaUntreated Adult Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2017-01-04
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT03009240
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath